These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study. Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869 [TBL] [Abstract][Full Text] [Related]
3. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
4. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553 [TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125 [TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF; Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461 [TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388 [TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660 [TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
10. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP]. Mori M; Kato M; Koh K; Hanada R Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675 [TBL] [Abstract][Full Text] [Related]
11. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224 [TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Al-Samkari H; Kuter DJ Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942 [TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia. Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329 [TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Gudbrandsdottir S; Frederiksen H; Hasselbalch H Platelets; 2012; 23(6):423-9. PubMed ID: 22185370 [TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
16. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview. Vibor M; Rogulj IM; Ostojic SK Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281 [TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era. Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624 [TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonists: ten years later. Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079 [TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127 [No Abstract] [Full Text] [Related] [Next] [New Search]